• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.02% Nasdaq Up0.09%

    OXiGENE, Inc. (OXGN)

    1.62 Down 0.01(0.58%) 9:41AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    OXiGENE, Inc.
    701 Gateway Boulevard
    Suite 210
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-635-7000
    Fax: 650-635-7001
    Website: http://www.oxigene.com

    Index Membership:N/A
    Full Time Employees:9

    Business Summary 

    OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression. Its principal clinical product candidate is ZYBRESTAT, which is in development as a treatment for solid tumors. The company is also developing OXi4503, a second-generation product candidate for acute myeloid leukemia. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on OXiGENE, Inc.

    Key Executives 
    Dr. David J. Chaplin Ph.D., 58
    Chief Exec. Officer, Pres and Director
    Ms. Barbara Riching , 55
    Chief Financial Officer and Principal Accounting Officer
    Ms. Shari Annes ,
    Exec. Officer of Investor Relations
    Dr. Yuval Binur Ph.D.,
    Exec. VP of Financial
    Lisa Powell ,
    Assistant Sec.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders